Currently, 6 months of androgen deprivation
therapy (ADT) plus radiotherapy is the standard treatment for unfavorable-risk localized prostate cancer.
Radiotherapy and short term androgen deprivation
for localized prostate cancer.
4]] Enzalutamide is now approved in Europe for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation
therapy in whom chemotherapy is not yet clinically indicated.
The objective of the trial was to determine whether survival using intermittent androgen deprivation
would provide better survival rates and quality of life for men compared to continuous androgen deprivation
They die off when starved of androgens, thus prolonging the effects of androgen deprivation
, which ultimately prolongs the patient's life.
therapy (ADT) is the mainstay treatment for men with advanced prostate cancer.
Because prostate cancer cells depend on androgen, standard treatments of prostate cancer involve targeting androgen receptor function, called androgen deprivation
Accepted treatments for prostate cancer include surgery, radiotherapy, androgen deprivation
therapy (ADT), and chemotherapy.
But long-term use of hormone therapy, also known as androgen deprivation
Because no adequate randomized trials have compared active treatments for localized prostate cancer, the authors analyzed risk-adjusted, cancer-specific mortality outcomes among men who underwent radical prostatectomy, external-beam radiation therapy, or primary androgen deprivation
Bone loss can be a significant side effect for older men undergoing androgen deprivation
therapy (ADT) for treatment of prostate cancer.
also was seeking approval of the human IgG2 monoclonal antibody to treat and prevent bone loss in women with breast cancer receiving hormone ablation therapy and to treat and prevent bone loss in men with prostate cancer receiving androgen deprivation